Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Takeda (Details)

v3.21.2
Licensing and Other Arrangements - Takeda (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Nov. 16, 2020
Feb. 28, 2009
Nov. 30, 2006
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Licensing and other arrangements                
Revenue from contracts with customers       $ 550 $ 200 $ 1,094 $ 753  
Takeda | Collaboration agreement                
Licensing and other arrangements                
Revenue from contracts with customers $ 2,000     0 $ 0 0 $ 0  
Contract assets       0   0   $ 0
Capitalized contract costs       $ 0   $ 0   $ 0
Takeda | Collaboration agreement | TAK-079                
Licensing and other arrangements                
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones     $ 19,000          
Royalty payment period from the first commercial sale of each royalty-bearing discovery product     13 years 6 months          
Royalty payment period from first commercial sale if there is significant generic competition post patent-expiration     12 years          
Takeda | Collaboration agreement | Other antibodies                
Licensing and other arrangements                
Maximum eligible milestone payments receivable per discovery product candidate   $ 3,300            
Royalty payment period   10 years